. 2021 Jun 24;16(6):e0251646. doi: 10.1371/journal.pone.0251646

Table 2. Insulin levels of rats in each group at weeks 0, 2, 4, 6, and 8.

Week	Control (μg l^-1)	STZ (μg l^-1)	STZ + 1× Probioglu^TM (μg l^-1)	STZ + 5× Probioglu^TM (μg l^-1)	STZ + 10× Probioglu^TM (μg l^-1)
0	0.90 ± 0.05	0.90 ± 0.06	0.93 ± 0.04	0.91 ± 0.05	0.90 ± 0.06
2	0.92 ± 0.03	1.93 ± 0.09^#	1.89 ± 0.08 ^#	1.69 ± 0.13^#^*	1.50 ± 0.2 ^#^*
4	0.95 ± 0.03	2.35 ± 0.28^#	2.13 ± 0.10^#^*	1.76 ± 0.14^#^*	1.56 ± 0.19^#^*
6	1.01 ± 0.04	2.42 ± 0.29^#	2.20 ± 0.07^#^*	1.97 ± 0.16^#^*	1.63 ± 0.16^#^*
8	1.08 ± 0.03	3.38 ± 0.15^#	2.61 ± 0.10^#^*	2.35 ± 0.06^#^*	2.18 ± 0.12^#^*

Untreated rats (control group), streptozotocin (STZ)-treated rats (STZ group), and STZ + ProbiogluTM-treated rats (STZ + 1× Probioglu^TM group, 5.17 × 10⁹ CFU kg^-1 d^-1; STZ + 5× Probioglu^TM group, 2.58 × 10¹⁰ CFU kg^-1 d^-1; STZ + 10× Probioglu^TM group, 5.17 × 10¹⁰ CFU kg^-1 d^-1). Each group consisted of 8 rats in this study.

* indicates a significant difference compared with the STZ group at p < 0.05

# represents a significant difference compared to the control group at p < 0.05.